n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide has been researched along with Angiogenesis, Pathologic in 21 studies
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide: structure given in first source
NS-398 : A C-nitro compound that is N-methylsulfonyl-4-nitroaniline bearing an additional cyclohexyloxy substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lung cancer is one of the most common causes of cancer-related mortality throughout the world, and the incidence continues to increase." | 2.42 | COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. ( Choy, H; Pyo, H; Saha, D, 2003) |
| "To investigate the function of COX-2 in prostate cancer directly, we stably transfected human full-length COX-2 cDNA into LNCaP cells (LNCaP-COX-2), which express low levels of endogenous COX-2." | 1.31 | Cyclooxygenase-2 promotes prostate cancer progression. ( Fujita, H; Keller, ET; Koshida, K; Mizokami, A; Namiki, M; Takahashi, Y; Yoshimito, T, 2002) |
| "However, NSAIDs produce gastroduodenal ulcers in about 25% of users (often with bleeding and/or perforations) and delay ulcer healing, presumably by blocking prostaglandin synthesis from cyclooxygenase (COX)-1 and COX-2 (ref." | 1.30 | Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. ( Itani, RM; Jones, MK; Levin, E; Peskar, BM; Sarfeh, IJ; Tarnawski, AS; Wang, H, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 16 (76.19) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, H | 2 |
| Ito, Y | 1 |
| Suzuki, T | 1 |
| Kato, S | 1 |
| Matsui, Y | 1 |
| Ogawa, F | 1 |
| Murata, T | 1 |
| Sugimoto, Y | 1 |
| Senior, R | 1 |
| Kitasato, H | 2 |
| Hayashi, I | 2 |
| Satoh, Y | 1 |
| Narumiya, S | 1 |
| Majima, M | 2 |
| Muraki, C | 1 |
| Ohga, N | 1 |
| Hida, Y | 1 |
| Nishihara, H | 1 |
| Kato, Y | 1 |
| Tsuchiya, K | 1 |
| Matsuda, K | 1 |
| Totsuka, Y | 1 |
| Shindoh, M | 1 |
| Hida, K | 1 |
| Banu, NA | 1 |
| Daly, RS | 1 |
| Buda, A | 1 |
| Moorghen, M | 1 |
| Baker, J | 1 |
| Pignatelli, M | 1 |
| Silver, K | 1 |
| Desormaux, A | 1 |
| Freeman, LC | 1 |
| Lillich, JD | 1 |
| Fujita, H | 1 |
| Koshida, K | 1 |
| Keller, ET | 1 |
| Takahashi, Y | 1 |
| Yoshimito, T | 1 |
| Namiki, M | 1 |
| Mizokami, A | 1 |
| Chu, J | 1 |
| Lloyd, FL | 1 |
| Trifan, OC | 1 |
| Knapp, B | 1 |
| Rizzo, MT | 1 |
| Saha, D | 1 |
| Pyo, H | 1 |
| Choy, H | 1 |
| Yoshida, S | 1 |
| Kamata, M | 1 |
| Inukai, M | 1 |
| Yoshimura, H | 1 |
| Chen, Q | 1 |
| Shinohara, N | 1 |
| Abe, T | 1 |
| Watanabe, T | 1 |
| Nonomura, K | 1 |
| Koyanagi, T | 1 |
| Devesa, I | 1 |
| Alcaraz, MJ | 1 |
| Riguera, R | 1 |
| Ferrándiz, ML | 1 |
| Zhong, H | 1 |
| Willard, M | 1 |
| Simons, J | 1 |
| Huang, SP | 1 |
| Wu, MS | 1 |
| Shun, CT | 1 |
| Wang, HP | 1 |
| Hsieh, CY | 1 |
| Kuo, ML | 1 |
| Lin, JT | 1 |
| Fu, YG | 1 |
| Sung, JJ | 1 |
| Wu, KC | 1 |
| Wu, HP | 1 |
| Yu, J | 1 |
| Chan, M | 1 |
| Chan, VY | 1 |
| Chan, KK | 1 |
| Fan, DM | 1 |
| Leung, WK | 1 |
| Ferrario, A | 1 |
| Fisher, AM | 1 |
| Rucker, N | 1 |
| Gomer, CJ | 1 |
| Ozawa, Y | 1 |
| Murakami, T | 1 |
| Tamura, M | 1 |
| Terada, Y | 1 |
| Yaegashi, N | 1 |
| Okamura, K | 1 |
| Jones, MK | 2 |
| Wang, H | 1 |
| Peskar, BM | 1 |
| Levin, E | 1 |
| Itani, RM | 1 |
| Sarfeh, IJ | 1 |
| Tarnawski, AS | 2 |
| Sawaoka, H | 1 |
| Tsuji, S | 1 |
| Tsujii, M | 1 |
| Gunawan, ES | 1 |
| Sasaki, Y | 1 |
| Kawano, S | 1 |
| Hori, M | 1 |
| Liu, XH | 1 |
| Kirschenbaum, A | 1 |
| Yao, S | 1 |
| Lee, R | 1 |
| Holland, JF | 1 |
| Levine, AC | 1 |
| Rozic, JG | 1 |
| Chakraborty, C | 1 |
| Lala, PK | 1 |
| Shimamura, M | 1 |
| Hazato, T | 1 |
| Ashino, H | 1 |
| Yamamoto, Y | 1 |
| Iwasaki, E | 1 |
| Tobe, H | 1 |
| Yamamoto, K | 1 |
| Yamamoto, S | 1 |
| Szabó, IL | 1 |
| Kawanaka, H | 1 |
| Husain, SS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
1 review available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Cyclooxygenase 2 | 2003 |
20 other studies available for n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
Topics: Animals; Cyclooxygenase 2; Humans; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Neopl | 2009 |
Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.
Topics: Animals; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cy | 2012 |
Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation.
Topics: 1,2-Dimethylhydrazine; Adenoma; Animals; Apoptosis; beta Catenin; Bromodeoxyuridine; Carcinogens; Ce | 2011 |
Expression of pleiotrophin, an important regulator of cell migration, is inhibited in intestinal epithelial cells by treatment with non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Carrier Proteins; Cell Line; Cell | 2012 |
Cyclooxygenase-2 promotes prostate cancer progression.
Topics: Animals; Blotting, Western; Cell Division; Cyclooxygenase 2; Endothelial Growth Factors; Gene Expres | 2002 |
Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer.
Topics: Capillaries; Cell Division; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2003 |
COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.
Topics: Animals; Antibodies, Blocking; Aspirin; Benzenesulfonates; Carcinoma, Lewis Lung; Cyclooxygenase Inh | 2003 |
Significance of COX-2 expression in human renal cell carcinoma cell lines.
Topics: Animals; Apoptosis; Blotting, Western; Butyrates; Carcinoma, Renal Cell; Cell Division; Cell Line, T | 2004 |
A new pyrazolo pyrimidine derivative inhibitor of cyclooxygenase-2 with anti-angiogenic activity.
Topics: Angiogenesis Inhibitors; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloo | 2004 |
NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms.
Topics: Cell Hypoxia; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA-Binding | 2004 |
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma.
Topics: Adult; Aged; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibit | 2005 |
Inhibition of gastric cancer-associated angiogenesis by antisense COX-2 transfectants.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA, Antisense; DNA, Compl | 2005 |
Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase Inhibitors; Dihematoporphyrin Ether; Dinoprostone; Dru | 2005 |
A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice.
Topics: Adult; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Vessels; Cell Proliferation; Cyclooxygenas | 2006 |
Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase | 1999 |
Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Topics: Animals; Apoptosis; Cell Division; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 1999 |
Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
Topics: Animals; Apoptosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diseas | 2000 |
Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis.
Topics: Animals; Cell Division; Cell Movement; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2001 |
Inhibition of angiogenesis by humulone, a bitter acid from beer hop.
Topics: Allantois; Animals; Beer; Cell Division; Cells, Cultured; Chick Embryo; Chorion; Cyclohexenes; Cyclo | 2001 |
von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Hypoxia; Cell Line; Endothelial Growth Factor | 2002 |